Grainger (GWW) Q4 2025 earnings review
Endless Assortment Carries the Quarter; FY26 Guidance Signals Acceleration
Grainger closed FY25 with a mixed Q4. While total sales grew 4.5% to $4.4B, the quality of growth was lopsided. The core High-Touch Solutions (N.A.) segment effectively stalled (+2.2%), relying on the Endless Assortment segment (+14.3%) to drive the topline. Margins compressed 70bps due to 'unforeseen healthcare costs' and sluggish core volume. However, the narrative shifts positively with FY26 guidance: management forecasts daily organic sales growth accelerating to 6.5%-9.0% and EPS jumping to a midpoint of $43.50, suggesting confidence that the U.K. exit and tariff headwinds are now in the rearview mirror.
🐂 Bull Case
Management projects FY26 daily organic sales growth of 6.5-9.0%, a significant acceleration from the ~4.9% pace in FY25. This suggests they expect a macro recovery or significant share gains following the U.K. market exit.
The online-centric segment (Zoro/MonotaRO) continues to be a powerhouse, growing 14.3% in Q4 and expanding gross margins by 70bps. It is successfully offsetting the maturity curve of the core industrial business.
🐻 Bear Case
High-Touch Solutions North America, which generates the bulk of profits, grew only 2.2% in Q4 (2.1% daily constant currency). Volume growth is anemic, raising concerns about market share saturation in the core MRO space.
Operating margin fell 70bps to 14.3%. Management cited 'unforeseen healthcare costs'—a red flag for expense forecasting—alongside the inability to leverage fixed costs on slower sales growth.
⚖️ Verdict: 🟢
Bullish. Despite a messy Q4 (margin compression, tax headwinds), the FY26 guidance is surprisingly strong. The projected acceleration in organic growth and the removal of the U.K. drag position the company for a cleaner, more profitable year ahead.
Key Themes
High-Touch Solutions Deceleration
The core North American business is losing momentum. Sales growth decelerated to 2.2% in Q4, down from 3.4% in Q3. Operating margin in this segment was hit by 'slower sales growth' and higher expenses. Since this segment carries the highest margins (typically ~17%), its stagnation is a drag on the entire P&L.
Endless Assortment Outperformance
MonotaRO and Zoro continue to justify their valuation premium. Segment sales jumped 14.3% in Q4 (15.7% daily organic). Crucially, this growth is becoming more profitable: segment gross margin expanded 70 basis points YoY. This segment is no longer just a 'growth' story but a profitability contributor.
Operating Expense Surprise
Q4 Operating margin dropped to 14.3% from 15.0% a year ago. Management specifically flagged 'unforeseen healthcare costs' as a driver. While likely non-recurring, unexpected spikes in SG&A during a period of slowing core sales suggest a temporary loss of operating leverage.
Portfolio Clean-Up (U.K. Exit)
The Q3 announcement to exit the U.K. (Cromwell/Zoro U.K.) was completed in Q4. While this caused noise in FY25 financials (tax rate spikes, reported loss), it removes a long-term drag on margins and management attention. FY26 guidance benefits from this 'addition by subtraction.'
Tax Rate Headwinds
EPS growth is being suppressed by tax mechanics. The effective tax rate spiked to 22.8% in Q4 (vs 20.1% prior year) due to the U.K. exit loss lacking a tax benefit and the lapping of a prior year reserve release. This explains why Net Earnings fell 5.1% despite Sales rising 4.5%.
Gross Margin Pressure
Total gross margin dipped 10 bps to 39.5%. While Endless Assortment margins improved, the larger High-Touch segment faced headwinds from segment mix. The full-year margin decline of 30 bps (to 39.1%) reflects the lingering impact of tariff-related inflation and LIFO headwinds seen earlier in the year.
Other KPIs
Stable. Cash generation remains robust ($2.0B vs $2.1B in FY24), allowing for consistent capital returns. The company returned $1.5B to shareholders via dividends and buybacks in FY25, representing 75% of operating cash flow.
Decelerating. Full-year adjusted margin fell 50 basis points from 15.5% in FY24. This compression was driven by gross margin headwinds (tariffs/LIFO) and the inability to offset inflation fully with pricing in the High-Touch segment.
Stable. Inventory grew only ~3.8% YoY (from $2.31B), tracking slightly below sales growth of 4.5%. This indicates disciplined working capital management despite the supply chain noise earlier in the year.
Guidance
Accelerating. The guidance implies reported growth of 4.2%-6.7%. More importantly, the 'daily, organic constant currency' growth is guided to 6.5%-9.0%, a major step up from the ~4.9% achieved in FY25. This signals an expectation of stronger volumes.
Accelerating. The midpoint ($43.50) implies roughly 10% growth over FY25 Adjusted EPS ($39.48). This is a return to double-digit earnings growth after a flat/up 1% performance in FY25.
Reversing. After compressing to 15.0% (adjusted) in FY25, management expects margins to expand back toward 2024 levels (15.5%). This expansion is likely driven by the removal of U.K. losses and operating leverage on higher sales.
Accelerating. Guidance midpoint represents ~11% growth over FY25 actuals ($2.0B), consistent with the expected recovery in Net Income.
Key Questions
High-Touch Growth Assumptions
Core segment growth slowed to 2.2% in Q4. What specific macro indicators or internal initiatives underpin the confidence to guide FY26 daily organic growth up to the 6.5-9.0% range?
Healthcare Cost Visibility
Q4 margins were hit by 'unforeseen healthcare costs.' Was this a one-time claims spike or a structural repricing of benefits, and is it fully baked into the 15.4% margin floor for FY26?
Endless Assortment Margins
Endless Assortment gross margins expanded 70bps in Q4. Is this driven by mix shift within Zoro/MonotaRO or reduced promotional intensity, and is this trajectory sustainable in FY26?
Tariff Environment
With FY25 gross margins impacted by tariff-driven LIFO headwinds, does the FY26 gross margin guidance of 39.2%-39.5% assume a stable tariff environment or additional pricing actions?